Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
Adults who have struggled with weight loss despite diet and exercise Individuals who experience frequent hunger or difficulty controlling appetite Patients with signs of metabolic or hormonal challenges Those seeking a medically supervised weight loss program Individuals willing to participate in regular medical check-ins Patients looking for long-term weight management support Eligibility is determined by a licensed provider after a medical evaluation Who may Not be a Candidate
Lofton HF, Hold RP, Fielding G, Schwack B, Kaufman L, Oksman Z, et al
Wegovy, as an injection, is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity and adolescents ages 12 years and older with obesity Adults with overweight plus at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, or high cholesterol Treat a serious type of fatty liver disease called noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring (stage F2 to F3 fibrosis) Lower the risk of major cardiovascular problems (such as heart attack, stroke, and heart-related death) in adults with established cardiovascular disease and obesity or overweight Contrave is FDA approved to: Reduce excess body weight and maintain long-term weight reduction in: Adults with obesity, defined as a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher (overweight) plus at least one weight-related medical condition To recap, heres an at-a-glance comparison of FDA-approved uses for Wegovy vs
